Current Insights into the Novel Coronavirus Disease 2019 (COVID-19) and Its Homoeopathic Management
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a new coronavirus strain that has not been ever found in humans before December 2019. Both the coronavirus disease 2019 (COVID-19) case fatality rate and deaths per million population in the top 10 affected countries are increasing a lot due to ever-increasing number of new cases among countries facilitated by increased affinity of SARS-CoV-2 to bind human angiotensin-converting enzyme 2 (ACE2) receptors. While human-to-human transmission of SARS-CoV-2 happens through close contact with an infected individual who spreads respiratory droplets through air or other means, its diagnosis relies mainly on detection of nucleic acid. Repurposing drugs such as dexamethasone, remdesivir, favipiravir and TMPRSS2 (trans membrane protease, serine 2) protease inhibitors have been shown to be effective for the treatment of COVID-19 with albeit requirement of further studies to conclude their complete effectiveness. Personal protective measures should be followed to prevent SARS-CoV-2 infection. Additionally, hundreds of clinical trials of vaccines against SARS-CoV-2 are undergoing, while plasma therapy from the COVID-19 survivors is also being tried to treat the severely affected patients. In addition to these aforementioned modern medicines and therapeutic approaches, homoeopathy also holds promising anti-viral effect as evident from its success against flu and other epidemics, historically. Therefore, present article provides a glimpse of advancements made in the area of homoeopathic ways of treating COVID-19 by summarising the recent homoeopathic clinical, research trials and future scopes of homoeopathy to combat the pandemic. After critical review of most of the ongoing or recently completed homoeopathic treatment efforts against SARS-CoV-2, it was identified that Bryonia alba, Arsenicum album and Gelsemium sempervirens are working best among homoeopathic medicines till now. These studies are also suggesting an increased application of these remedies to treat the current pandemic worldwide; therefore, more such studies are warranted. Those further research will pave the way to understand the mechanism of each of these homoeopathic drugs to cure COVID-19 facilitated by optimising their doses, effects and find the best among these multiple options in homoeopathic medicines for plausible mono- or combination therapies.
KeywordsSARS-CoV-2 - COVID-19 - cytokine storm - Bryonia alba - Arsenicum album - Gelsemium sempervirens - ABO blood group - psychological impacts - homoeopathy
* Both authors contributed equally to the article.
16 September 2020 (online)
© 2020. Thieme. All rights reserved.
Thieme Medical and Scientific Publishers Private Ltd.
- 1 Saxena SK. Medical Virology: from Pathogenesis to Disease Control. . ISSN 2662–981X ISSN 2662–9828 (electronic) Medical Virology: from Pathogenesis to Disease Control ISBN 978–981–15–4813–0 ISBN 978–981–15–4814–7 (eBook) https://doi.org/10.1007/978-981-15-4814-7 1st ed.. Singapore: Springer Nature Singapore Pte Ltd; 2020: 1-122
- 2 Dey JK, Dey SK. SARS-CoV-2 Pandemic, COVID-19 Case Fatality Rates and Deaths per Million Population in India. Journal of Bioinformatics. Comp Syst Biol 2020; 2 (01) 110
- 3 COVID-19 Coronavirus Pandemic. Available at: https://www.worldometers.info/coronavirus/ . Accessed 20 June 2020
- 4 Cucinotta D, Vanelli M. WHO declares COVID-19 a pandemic. Acta Biomed 2020; 91 (01) 157-160
- 5 Ebrahim SH, Ahmed QA, Gozzer E, Schlagenhauf P, Memish ZA. Covid-19 and community mitigation strategies in a pandemic. BMJ 2020; 368: m1066 DOI: 10.1136/bmj.m1066.
- 6 Last JM. , ed. A Dictionary of Epidemiology. A Handbook sponsored by the IEA, Oxford, England: Oxford University Press; 1983
- 7 Park K. Park's textbook of Preventive and Social Medicine. 21st edition. Jabalpur, MP: M/s Banarsidas Bhanot Publishers; 2011: 89
- 8 Chan JF, Yuan S, Kok KH. , et al. A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person-to-person transmission: a study of a family cluster. Lancet 2020; 395 (10223): 514-523
- 9 Ghinai I, McPherson TD, Hunter JC. , et al. Illinois COVID-19 Investigation Team. First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. Lancet 2020; 395 (10230): 1137-1144
- 10 Zhang JJ, Dong X, Cao YY. , et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy 2020; 75 (07) 1730-1741
- 11 Zhao D, Yao F, Wang L. , et al. A comparative study on the clinical features of COVID-19 pneumonia to other pneumonias. Clin Infect Dis 2020; ciaa247 DOI: 10.1093/cid/ciaa247.
- 12 Xiong Y, Sun D, Liu Y. , et al. 2020 Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes. Investig Radiol. https://doi.org/10.1097/RLI.0000000000000674
- 13 Chinazzi M, Davis JT, Ajelli M. , et al. The effect of travel restrictions on the spread of the 2019 novel coronavirus (COVID-19) outbreak. Science 2020; 368 (6489): 395-400
- 14 WHO welcomes preliminary results about dexamethasone use in treating critically ill COVID-19 patients. Available at: https://www.who.int/news-room/detail/16-06-2020-who-welcomes-preliminary-results-about-dexamethasone-use-in-treating-critically-ill-covid-19-patients . Accessed 20 June 2020
- 15 Amanat F, Krammer F. SARS-CoV-2 vaccines: status report. Immunity 2020; 52 (04) 583-589
- 16 Teixeira da Silva JA. Convalescent plasma: A possible treatment of COVID-19 in India. Med J Armed Forces India 2020; DOI: 10.1016/j.mjafi.2020.04.006.
- 17 Chen L, Xiong J, Bao L, Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect Dis 2020; 20 (04) 398-400
- 18 Saxena SK, Manchanda RK. Handbook of Recent Trends in Homoeopathy for Infectious Diseases in India and Abroad. 1st ed.. New Delhi, India: Central Council for Research in Homoeopathy; 2016: 3
- 19 COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. (JHU). Available at: https://coronavirus.jhu.edu/map.html . Accessed 20 June 2020
- 20 Global Covid-19 Case Fatality Rates. Available at: https://www.cebm.net/covid-19/global-covid-19-case-fatality-rates/ . Accessed 20 June 2020
- 21 Statistics and Research. Coronavirus Pandemic (COVID-19). Available at: https://ourworldindata.org . Accessed 20 June 2020
- 22 Chan JF, Kok KH, Zhu Z. , et al. Genomic characterization of the 2019 novel human-pathogenic coronavirus isolated from a patient with atypical pneumonia after visiting Wuhan. Emerg Microbes Infect 2020; 9 (01) 221-236
- 23 Kim JM, Chung YS, Jo HJ. , et al. Identiﬁcation of coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res Perspect 2020; 11 (01) 3-7
- 24 Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science 2020; 367 (6485): 1444-1448
- 25 Kumar S, Maurya VK, Prasad AK, Bhatt MLB, Saxena SK. Structural, glycosylation and antigenic variation between 2019 novel coronavirus (2019-nCoV) and SARS coronavirus (SARS-CoV). Virusdisease 2020; 31 (01) 13-21
- 26 Walls AC, Park YJ, Tortorici MA, Wall A, McGuire AT, Veesler D. Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 2020; 181 (02) 281-292.e6
- 27 Li X, Geng M, Peng Y, Meng L, Lu S. Molecular immune pathogenesis and diagnosis of COVID-19. J Pharm Anal 2020; 10 (02) 102-108
- 28 Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. 2020; Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet 395 (10224): e35-e36 https://doi.org/10.1016/S0140–6736(20)30305–6
- 29 Zeng X, Fan H, Lu D. , et al. Association between ABO Blood Groups and Clinical Outcome of Coronavirus Disease 2019: Evidence from Two Cohorts. Medrxiv 2020 . Available at: https://www.medrxiv.org/content/10.1101/2020.04.15.20063107v1%20
- 30 Ellinghaus D, Degenhardt F, Bujanda L. et al. Genomewide association study of severe Covid-19 with respiratory failure. New Eng Med 2020; DOI: 10.1056/NEJMoa2020283.
- 31 Centre for Disease Control and Prevention. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens from Persons for Coronavirus Disease 2019 (COVID-19). 2020 . Available rom: https://www.cdc.gov/coronavirus/2019-ncov/lab/guidelinesclinical-specimens.html . Accessed 18 March 2020
- 32 Mahajan A, Sharma P. COVID-19 and radiologist: Image wisely. Indian J Med Paediatr Oncol [Epub ahead of print] [cited 2020 Jun 5]. Available from: http://www.ijmpo.org/preprintarticle.asp?id=285517 . Accessed 25 July 2020
- 33 Zhou S, Wang Y, Zhu T, Xia L. CT features of coronavirus disease 2019 (COVID-19) pneumonia in 62 patients in Wuhan, China. AJR Am J Roentgenol 2020; 214 (06) 1287-1294
- 34 Wang Y, Kang H, Liu X, Tong Z. Combination of RT-qPCR testing and clinical features for diagnosis of COVID-19 facilitates management of SARS-CoV-2 outbreak. J Med Virol 2020; 92 (06) 538-539
- 35 Li Z, Yi Y, Luo X. , et al. Development and clinical application of a rapid IgM-IgG combined antibody test for SARS-CoV-2 infection diagnosis. J Med Virol 2020; DOI: 10.1002/jmv.25727.
- 36 Centre for Disease Control and Prevention. Interim Infection Prevention and Control Recommendations for Patients with Suspected or Conﬁrmed Coronavirus Disease 2019 (COVID-19) in Healthcare Settings. 2020 . Available from: https://www.cdc.gov/coronavirus/2019-ncov/infection-control/control-recommendations.html . Accessed 18 March 2020
- 37 Gostic K, Gomez AC, Mummah RO, Kucharski AJ, Lloyd-Smith JO. Estimated effectiveness of symptom and risk screening to prevent the spread of COVID-19. eLife 2020; 9: e55570 DOI: 10.7554/eLife.55570.
- 38 U.S. National Library of Medicine. Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) to Prevent SARS-CoV-2 Infection. NCT04283461. 2020. Available from: https://clinicaltrials.gov/ct2/show/NCT04283461 . Accessed 18 March 2020
- 39 Centre for Disease Control and Prevention. Interim Clinical Guidance for Management of Patients with Conﬁrmed Coronavirus Disease (COVID-19). 2020 . Available from: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-guidance-managementpatients.html . Accessed 18 March 2020
- 40 Wang M, Cao R, Zhang L. , et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020; 30 (03) 269-271
- 41 Grein J, Ohmagari N, Shin D. , et al. Compassionate use of remdesivir for patients with severe Covid-19. N Engl J Med 2020; 382 (24) 2327-2336
- 42 Dong L, Hu S, Gao J. Discovering drugs to treat coronavirus disease 2019 (COVID-19). Drug Discov Ther 2020; 14 (01) 58-60
- 43 Yao X, Ye F, Zhang M. , et al. In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Clin Infect Dis 2020; ciaa237 DOI: 10.1093/cid/ciaa237.
- 44 Hoffmann M, Kleine-Weber H, Schroeder S. , et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell 2020; 181 (02) 271-280.e8
- 45 McCuskey EY. FDA in the Time of COVID-19. 2020 . ABA Admin. & Regulatory Law News, Vol. 45, No. 3, Available at SSRN: https://ssrn.com/abstract=3624538
- 46 Saxena SK, Manchanda RK. Handbook of Recent Trends in Homeopathy for Infectious Diseases in India and Abroad. 1st edition. New Delhi, India: Central Council for Research in Homoeopathy; 2016: 8
- 47 Hahnemann S. Organon of Medicine. 6th edition. B Jain Publishers; 2004: 267
- 48 Ullman D. Homeopathy: Medicine for the 21st Century. USA: North Atlantic Books, Berkeley; 1988: 33-54
- 49 Goddard J. Homeopathy in Epidemics and Pandemics. Available from: http://www.thecma.org.uk/cma_images/Jayney's%20Presentation.pdf . Accessed 25 July 2020
- 50 World Health Organisation. Ethical Considerations for Use of Unregistered Interventions for Ebola Virus Disease (EVD) Available from: https://www.who.int/mediacentre/news/statements/2014/ebola-ethical-review-summary/en/ . Accessed 11 March 2020
- 51 Press Information Bureau, Government of India. Advisory for Corona virus. Available from: https://pib.gov.in/pressreleasepage.aspx?prid=1600895 . Accessed 02 June 2020
- 52 Bellavite P, Signorini A, Marzotto M, Moratti E, Bonafini C, Olioso D. Cell sensitivity, non-linearity and inverse effects. Homeopathy 2015; 104 (02) 139-160
- 53 Parikh N, Parikh D. Role of Homoeopathy in COVID-19 Management- A Clinical Experience. World Journal of Pharmaceutical Research. 2020 May; 9 (5):2459–2466. Available from: https://wjpr.net/dashboard/abstract_id/14409 . Accessed 25 July 2020
- 54 Homeopathy Drug Untested for Efficacy against COVID-19 Widely Distributed in Mumbai. Available from: https://www.thehindu.com/news/cities/mumbai/placebo-effect-untested-homoeopathy-drug-being-distributed-widely/article31645532.ece . Accessed 25 July 2020
- 55 Symptomatic COVID-19 Positive and Likely Patients Treated Study. Available by homeopathic physicians-an Italian descriptive from: https://www.researchgate.net/publication/340631586_Symptomatic_COVID-19_positive_and_likely_patients_treated_by_homeopathic_physicians_-_an_Italian_descriptive_study . Accessed 3 May 2020
- 56 To KLA, Fok YYY. Homeopathic clinical features of 18 patients in COVID-19 outbreaks in Hong Kong. Homeopathy 2020; DOI: 10.1055/s-0040-1710545.
- 57 Moorthi SK, Radhika P, Muraleedharan KC. Psychological implications during the outbreak of COVID-19 and its homoeopathic management. Indian J Res Homoeopathy 2020; 14: 136-142